{Reference Type}: Journal Article
{Title}: Chronic myeloid leukaemia: Biology and therapy.
{Author}: Wang Y;Liang ZJ;Gale RP;Liao HZ;Ma J;Gong TJ;Shao YQ;Liang Y;
{Journal}: Blood Rev
{Volume}: 65
{Issue}: 0
{Year}: 2024 May 27
{Factor}: 10.626
{DOI}: 10.1016/j.blre.2024.101196
{Abstract}: Chronic myeloid leukaemia (CML) is caused by BCR::ABL1. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the optimal therapy goal. Which TKI is the best initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.